#ESCCongress – RCT: Finerenone reduced CV events in patients with kidney disease and type 2 diabetes (12.4% vs. 14.2% during a median follow-up of 3.4 years), but the risk of hyperkalemia was increased (10.8% vs. 5.3%).

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes – New England Journal of Medicine

News release: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology

Commentaries:

Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease – FIGARO-DKD – American College of Cardiology

FIGARO-DKD and FIDELITY Findings Show Benefits of Finerenone to Improve Outcomes in Patients With Kidney Disease, Diabetes – American College of Cardiology

Related:

[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes

Commentary on Twitter

FIGARO-DKD: Among patients with stage 1 to 4 CKD and T2 diabetes, finerenone improved CV outcomes as compared with placebo. #ESCCongress https://t.co/mcfmvftBvy pic.twitter.com/qizit80NBa

— NEJM (@NEJM) August 28, 2021